Plasma-Conditioned Liquids as Anticancer Therapies In Vivo: Current State and Future Directions.

摘要: Plasma-conditioned liquids (PCL) are gaining increasing attention in the medical field, especially oncology, and translation to clinics is advancing on a good path. This emerging technology involving cold plasmas has great potential as therapeutic approach cancer diseases, PCL have been shown selectively kill cells by triggering apoptotic mechanisms without damaging healthy cells. In this context, can be injected near tumor or intratumorally, thereby allowing treatment of malignant tumors located internal organs that not accessible for direct atmospheric plasma (CAP) treatment. Therefore, constitutes very interesting minimally invasive alternative CAP therapy, avoiding surgeries multiple local administrations. As field advances, it progressively moving evaluation effects vivo scenarios. Exciting developments pushing forward clinical novel therapy. However, there still room research, quantification identification reactive oxygen nitrogen species (RONS) conditions yet clarified, dosage regimens highly variable among studies, other more relevant models could used. work aims present critical review state anticancer agents applied studies.